Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 18;18(6):3123.
doi: 10.3390/ijerph18063123.

Flash Glucose Monitoring and Patient Satisfaction: A Meta-Review of Systematic Reviews

Affiliations
Review

Flash Glucose Monitoring and Patient Satisfaction: A Meta-Review of Systematic Reviews

Ana Díez-Fernández et al. Int J Environ Res Public Health. .

Abstract

Flash glucose monitoring (FGM) systems have been suggested to have clinical beneficial effects in patients with diabetes mellitus, although their improvements in terms of quality of life (QoL) and patients' satisfaction are not always addressed or are considered a secondary outcome. Thus, the aim of this meta-review is to establish the benefits of FGM in terms of patients' satisfaction and QoL in both type 1 and type 2 diabetes patients using evidence from past systematic reviews and meta-analyses. Major databases were searched for systematic reviews (with or without meta-analyses) that assessed the satisfaction or QoL of type 1 or 2 diabetes patients using FGM compared with other glucose monitoring systems. The quality of the included systematic reviews was addressed with the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool. Six systematic reviews (including two meta-analyses) were included in the meta-review. Evidence suggests that FGM systems seem to improve patients' satisfaction and QoL compared with self-monitoring of blood glucose, although the high variability in the measurement tools, the clinical significance and the quality of the systematic reviews included do not allow us to state FGM benefits with any certainty. Further research, including high-quality randomised clinical trials, differentiating the needs of both type 1 and type 2 diabetes patients and focusing on psychosocial benefits for these patients is needed to optimise clinical decisions between patients and professionals by developing the right health technology assessment for FGM systems.

Keywords: diabetes mellitus; flash glucose monitoring; meta-review; patients’ satisfaction; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Literature search Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) consort diagram.

Similar articles

Cited by

References

    1. American Diabetes Association 4. Lifestyle Management. [(accessed on 3 November 2020)];Diabetes Care. 2017 40(Suppl. 1):S33–S43. doi: 10.2337/dc17-S007. Available online: https://care.diabetesjournals.org/content/40/Supplement_1/S33. - DOI - PubMed
    1. Grant A.K., Golden L. Technological Advancements in the Management of Type 2 Diabetes. Curr. Diabetes Rep. 2019;19:163. doi: 10.1007/s11892-019-1278-3. - DOI - PubMed
    1. Cappon G., Acciaroli G., Vettoretti M., Facchinetti A., Sparacino G. Wearable continuous glucose monitoring sensors: A revolution in diabetes treatment. Electronics. 2017;6:65. doi: 10.3390/electronics6030065. - DOI
    1. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Group Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. [(accessed on 3 November 2020)];N. Engl. J. Med. 2008 359:1464–1476. doi: 10.1056/NEJMoa0805017. doi: 10.1056/NEJMoa0805017. Available online: - DOI - DOI - PubMed
    1. Leelarathna L., Wilmot E.G. Flash forward: A review of flash glucose monitoring. Diabetes Med. 2018;35:472–482. doi: 10.1111/dme.13584. - DOI - PubMed